Galecto, Inc. develops small molecules for the treatment of severe liver diseases, including inflammation, fibrosis and cancer. The company, founded in 2011, builds on more than 12 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets provide Galecto with a unique therapeutic platform.